

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**BOEHRINGER INGELHEIM PHARMACEUTICALS**

2. Address:

1201 PENNSYLVANIA AVE NW # 315, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

4. Contact Name: HENRY W. MENN III

Telephone: 2023478270

E-mail (optional): hmenn@rdg.boehringer-ingelheim.com

Senate ID #: 292972-12

House ID #:

7. Client Name: ☒ Self

## TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 713,336.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

☒ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: BOEHRINGER INGELHEIM PHARMACEUTICALS Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: ANI (one per page)

16. Specific lobbying issues:

HR. 4239, Animal Enterprise Terrorism Act S. 1926, Animal Terrorism Act

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: MORRIS, KRISTEN D. W.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BOEHRINGER INGELHEIM PHARMACEUTICALS Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

HR. 3010, Making Appropriations for the Departments of Labor, Health and Human Services and Education for FY 2007 S. 3708, Making Appropriations for the Departments of Labor, Health and Human Services and Education for FY 2007 HR. 544, Making Appropriation for the Department of Homeland Security for FY 2007 S. CON. RES. 83, Congressional Budget for Government for FY 2007 HR. 2744 Making Appropriations for Agriculture, Rural Development, Food and Drug Administration and Related Agencies for FY 2007

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: MENN III, HENRY W.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BOEHRINGER INGELHEIM PHARMACEUTICALS Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S.3818, Patent Reform Act of 2006 HR 2795, relating to the procurement, enforcement and validity of patents

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: MORRIS, KRISTEN D. W.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

HR. 5009, Ryan White CARE Act Amendments of 2006 Issues relating to pharmaceutical compounding Issues relating to Medicare Part D Issues relating to CFC Supply and essentiality S. 3807, Enhancing Drug Safety and Innovation Act of 2006 S. 4016 and HR. 6257, Access to Life Saving Medicine Act S. 3695, relating to the prohibition of authorized generic drugs HR. 328, Pharmaceutical Market Access Act of 2005 S. 109, Pharmaceutical Market Access Act of 2005 HR. 6143, The Ryan White HIV/AIDS Treatment Modernization Act S. 2339, Ryan White CARE Act Amendments of 2006

17. House(s) of Congress and Federal agencies contacted:

Environmental Protection Agency (EPA)  
Food & Drug Administration (FDA)  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
SENATE  
State, Dept of (DOS)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: MENN III, HENRY W.

Covered Official Position (if applicable): N/A

Name: MORRIS, KRISTEN D. W.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: IMM (one per page)

16. Specific lobbying issues:

Issues pertaining to H-1B Visa

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: MORRIS, KRISTEN D. W.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BOEHRINGER INGELHEIM PHARMACEUTICALS Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

HR. 6111 Tax Relief and Health Care Act of 2006 HR. 4944, Miscellaneous Trade and Technical Corrections Act of 2006 S. 2505, Duty Suspension on aerosol valves S. 3549, Foreign Investment and National Security Act of 2006 HR. 5337, National Security Foreign Investment Reform and Strengthened Transparency Act of 2006

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: MORRIS, KRISTEN D. W.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Signature: ON FILE Date: Feb 09, 2007

Printed Name and Title: HENRY W. MENN III, EXECUTIVE DIRECTOR, GOVERNMENT -